Aligos Therapeutics Reports Q3 Earnings with EPS Beat and Revenue Miss
Aligos Therapeutics (NASDAQ: ALGS) reported third-quarter financial results characterized by a mixed performance. The company posted a GAAP earnings per share (EPS) of -$2.09, which exceeded analyst expectations by $0.19. However, the company's revenue for the quarter reached only $2.83 million, falling significantly short of estimates by $2.71 million. This discrepancy highlights a substantial gap between projected and actual top-line performance despite the improved bottom-line results.
Topics: earnings_beat GAAP_EPS revenue_miss